Department of Otolaryngology

Medicine & Life Sciences

1. Sudden Hearing Loss 100%
2. Taiwan 98%
3. Sensorineural Hearing Loss 85%
4. Population 67%
5. Nasopharyngeal Carcinoma 54%
6. Salivary Gland Calculi 43%
7. Cohort Studies 43%
8. Cochlear Implants 43%
9. Nose 37%
10. Databases 32%
11. Myringoplasty 29%
12. Confidence Intervals 27%
13. Case-Control Studies 26%
14. Hearing 25%
15. Trachea 24%
16. Child 24%
17. Obstructive Sleep Apnea 24%
18. Neck 23%
19. Odds Ratio 23%
20. Incidence 23%
21. Neoplasms 23%
22. Otolaryngology 23%
23. Hearing Loss 23%
24. Hydroxymethylglutaryl-CoA Reductase Inhibitors 23%
25. Ovalbumin 22%
26. Health Insurance 21%
27. Tympanoplasty 21%
28. Allergic Rhinitis 20%
29. Head and Neck Neoplasms 20%
30. Survival 19%
31. Mouth Neoplasms 18%
32. Radiotherapy 18%
33. Squamous Cell Carcinoma of Head and Neck 17%
34. Ear Canal 17%
35. ovatodiolide 16%
36. Cholesteatoma 16%
37. Otitis Media 16%
38. Logistic Models 15%
39. poly(lactide) 15%
40. Comorbidity 15%
41. Nasopharyngeal Neoplasms 14%
42. Temperature 14%
43. hesperetin 14%
44. Smartphone 14%
45. Therapeutics 14%
46. Sialadenitis 14%
47. Neoplasm Metastasis 14%
48. Xylazine 14%
49. Iron-Deficiency Anemias 13%
50. Smooth Muscle 13%
51. Solid-State Lasers 13%
52. Rolipram 13%
53. Carcinoma 13%
54. Salivary Glands 13%
55. Salivary Ducts 13%
56. Head 13%
57. Foreign Bodies 12%
58. Histiocytic Necrotizing Lymphadenitis 12%
59. Sinusitis 12%
60. Tympanic Membrane Perforation 12%
61. Retrospective Studies 12%
62. Squamous Cell Carcinoma 12%
63. Type 4 Cyclic Nucleotide Phosphodiesterase 11%
64. Zinc 11%
65. Parotid Gland 11%
66. Electric Stimulation 11%
67. Phosphodiesterase 4 Inhibitors 11%
68. Ketamine 11%
69. Tongue 11%
70. Systemic Lupus Erythematosus 11%
71. Bell Palsy 11%
72. Pediatrics 11%
73. Submandibular Gland 10%
74. Guinea Pigs 10%
75. Vocal Cords 10%
76. National Health Programs 10%
77. Annexins 10%
78. Bone Conduction 10%
79. hesperetin-7,3'-O-dimethylether 10%
80. Laser Lithotripsy 10%
81. Audiometry 10%
82. Tension-Type Headache 10%
83. Methacholine Chloride 10%
84. Retinal Vein Occlusion 10%
85. Facial Nerve 10%
86. Mechanistic Target of Rapamycin Complex 1 9%
87. Nasal Mucosa 9%
88. Temozolomide 9%
89. Tonsillectomy 9%
90. Menthol 9%
91. Triple Negative Breast Neoplasms 9%
92. Phosphoric Diester Hydrolases 9%
93. Nasal Obstruction 9%
94. Neonatal Screening 9%
95. Stroke 9%
96. Autophagy 9%
97. Transplants 9%
98. Down-Regulation 9%
99. Paclitaxel 9%